Intractable intracranial tuberculous infection responsive to thalidomide: Report of four cases

Journal of Child Neurology

Volumn 21, Issue 4, 2006, Pages 301-308

  Schoeman, Johan F ^a   Fieggen, Graham ^b   Seller, Neil ^a   Mendelson, Marc ^c   Hartzenberg, Bennie ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CORTICOSTEROID; ETHIONAMIDE; ISONIAZID; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARACHNOIDITIS; ARTICLE; BACTERIOLOGY; BRAIN ABSCESS; BRAIN INFECTION; BRAIN SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; DRUG RESPONSE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; MALE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT FAILURE; VISUAL IMPAIRMENT;

ARACHNOIDITIS; BLINDNESS; BRAIN; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; THALIDOMIDE; TREATMENT OUTCOME; TUBERCULOMA, INTRACRANIAL;

EID: 33745151457     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738060210040801     Document Type: Article

References (23)

1. Afghani B, Lieberman JM: Paradoxical enlargement or development of intracranial tuberculomas during therapy: Case report and review. Clin Infect Dis 1994;19:1092-1099.
2. Chambers ST, Hendrickse WA, Record C, et al: Paradoxical expansion of tuberculomas during chemotherapy. Lancet 1984;2:181-183.
3. De Castro CC, de Barros NG, de Sousa Campos ZM, Cerri GG: CT scans of cranial tuberculosis. Radiol Clin North Am 1995;33: 753-769.
4. Gropper MR, Schulder M, Sharan AD, Cho E: Central nervous system tuberculosis: Medical management and surgical indications. Surg Neurol 1995;44:378-385.
5. Henrickson M, Weisse ME: Tuberculous brain abscess in a three-year-old South Pacific Islander. Pediatr Infect Dis J 1992;11: 488-491.
6. Tsenova L, Sokol K, Freedman VH, Kaplan G: A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998;177:1563-1572.
7. Schoeman JF, Ravenscroft A, Hartzenberg HB: Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess. Childs Nerv Syst 2001;17: 370-372.
8. Roberts MTM, Mendelson M, Meyer P, et al: The use of thalidomide in the treatment of intracranial tuberculomas. J Infect 2003;47:251-255.
9. Schoeman JF, Springer P, Janse van Rensburg A, et al: Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study. J Child Neurol 2004;19:250-257.
10. Schoeman JF, Donald PR, Van Zyl LE, Laubscher JA: Serial CT scanning in childhood tuberculous meningitis: Prognostic features in 198 cases. J Child Neurol 1995;10:320-329.
11. Rao GO, Nadh BR, Hemaratnan A, et al: Paradoxical progression of tuberculous lesions during chemotherapy of central nervous system tuberculosis. J Neurosurg 1995;83:359-362.
12. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR: Effect of corticosteroids on intracranial pressure, computerized tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226-231.
13. Garg RK: Tuberculosis of the central nervous system. J Postgrad Med 1999;75:133-140.
14. Donald PR, Schoeman JF, Beyers N, et al: Concentrations of interferon-γ, tumor necrosis factor-α and interleukin 1 in the cerebrospinal fluid of children treated for tuberculous meningitis. Clin Infect Dis 1995;21:924-929.
15. Schoeman JF, Springer P, Ravenscroft A, et al: Adjunctive thalidomide therapy of childhood tuberculosis meningitis: A possible anti-inflammatory role. J Child Neurol 2000;15:497-503.
16. Sampaio EP, Sarno EN, Galilly R, et al: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:1675-1680.
17. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-257.
18. Tramontana JM, Utaipat U, Moloy A, et al: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-397.
19. Gori A, Rossi MC, Trabattoni D, et al: Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. J Infect Dis 2000;182:639-40.
20. Bekker LG, Haslett PA, Maartens G, et al: Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type I and tuberculosis. J Infect Dis 2000;181:954-965.
21. Haslett PA, Corral LG, Albert M, Kaplan G: Thalidomide co-stimulates primary human T lymphocytes preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187: 1885-1892.
22. Marriott JB, Clarke IA, Dredge K, et al: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130:75-84.
23. Cavaletti G, Beronio A, Reni L, et al: Thalidomide sensory neurotoxicity: A clinical and neurophysiological study. Neurology 2004;62:2291-2293.